VivoSim director granted 15,000 stock units

VivoSim Labs, Inc. director Milhous Alison Tjosvold was granted 15,000 shares of common stock on January 27, 2026.

Accepted by SEC EDGAR 01/29/2026 - 07:51 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

VivoSim Labs, Inc. director Milhous Alison Tjosvold was granted 15,000 shares of common stock on January 27, 2026. The award is represented by restricted stock units that will vest on the earlier of January 27, 2027, or the next annual stockholder meeting, with potential acceleration upon a change of control. After this grant, the director beneficially owns 19,899 shares of common stock. All share amounts already reflect a 1-for-12 reverse stock split that became effective on March 20, 2025.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Milhous Alison Tjosvold

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 19,899 shares (Direct)

Holdings Before and After: Common Stock, 4,899 to 19,899 shares (Direct)

Footnotes (2)

1. F1. The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.
2. F2. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VivoSim Labs (VIVS) report on January 27, 2026?

VivoSim Labs reported a grant of 15,000 shares of common stock to director Milhous Alison Tjosvold. The shares are in the form of restricted stock units that vest based on time or the next annual stockholder meeting, with all amounts reflecting a prior reverse stock split.

Who received shares in the latest VivoSim Labs (VIVS) Form 4 filing?

Director Milhous Alison Tjosvold received 15,000 shares of VivoSim Labs common stock. The grant is structured as restricted stock units that vest on a future date or the next annual meeting, and it increased the director’s beneficial ownership to 19,899 shares.

How many VivoSim Labs (VIVS) shares does the reporting director own after the transaction?

After the reported transaction, director Milhous Alison Tjosvold beneficially owns 19,899 shares of VivoSim Labs common stock. This total includes the 15,000-share restricted stock unit grant and reflects the company’s 1-for-12 reverse stock split effective March 20, 2025.

When do the VivoSim Labs (VIVS) restricted stock units granted to the director vest?

The restricted stock units vest on the earlier of January 27, 2027, or the date of VivoSim Labs’ next annual stockholder meeting. Vesting is also subject to acceleration if a change of control occurs, which may cause earlier settlement of the award under specified conditions.

How did VivoSim Labs’ reverse stock split affect the Form 4 share numbers?

VivoSim Labs completed a 1-for-12 reverse stock split of its common stock effective March 20, 2025. All share amounts in the Form 4, including the 15,000-share grant and 19,899 shares owned after the transaction, already give effect to this reverse split adjustment.

What was the price per share for the VivoSim Labs (VIVS) director stock grant?

The 15,000-share grant to director Milhous Alison Tjosvold was reported at a price of $0 per share. This indicates an equity award of restricted stock units rather than an open-market purchase, with future vesting based on time or corporate meeting milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milhous Alison Tjosvold

(Last) (First) (Middle)

11555 SORRENTO VALLEY ROAD

SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VivoSim Labs, INC. [ VIVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		A		15,000(1)	A	$0	19,899(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control.

2. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Norman Staskey, attorney-in-fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.